Emerging Anti-Inflammatory Pharmacotherapy and Cell-Based Therapy for Lymphedema

Area of Science:

• Immunology
• Regenerative Medicine
• Oncology Supportive Care

Background:

• Secondary lymphedema frequently complicates cancer treatments like lymph node dissection and radiation.
• Current treatments alleviate symptoms but do not address the underlying pathophysiology.
• CD4+ T cell activation and accumulation are identified as critical factors in lymphedema development.

Purpose of the Study:

• To review the role of inflammatory cells in lymphedema pathogenesis.
• To discuss the efficacy and challenges of pharmacotherapy and cell-based therapies for lymphedema.
• To highlight mesenchymal stem/stromal cells (MSCs) as a promising cell-based therapy.

Main Methods:

• Review of recent advances in lymphedema pathophysiology.
• Analysis of preclinical (animal models) and pilot clinical studies on novel therapies.
• Focus on inflammatory cell involvement and therapeutic targets.

Main Results:

• Pharmacotherapies (tacrolimus, anti-IL-4/IL-13 antibody, fingolimod) and cell-based therapies show efficacy in models and pilot studies.
• Mesenchymal stem/stromal cells (MSCs) demonstrate long-term symptom improvement and edema reduction with a good safety profile.
• MSC transplantation promotes lymphatic regeneration and improves the tumor microenvironment in animal models.

Conclusions:

• Targeting CD4+ T cells and the inflammatory microenvironment represents a promising therapeutic strategy for secondary lymphedema.
• Mesenchymal stem/stromal cells (MSCs) offer a potentially curative approach by addressing pathophysiology and promoting lymphatic repair.
• Further research is needed to overcome challenges and optimize pharmacotherapy and cell-based treatments for lymphedema.